Clinical meaning
Drug-protein binding is a critical pharmacokinetic parameter that determines the free (unbound) fraction of a drug available for pharmacological activity, metabolism, and excretion. Most drugs bind reversibly to plasma proteins, primarily albumin (for acidic drugs such as warfarin, phenytoin, and NSAIDs) and alpha-1 acid glycoprotein (AAG, for basic drugs such as lidocaine and propranolol). Only the unbound fraction crosses cell membranes, reaches target receptors, undergoes hepatic metabolism, and is filtered by the glomerulus. Highly protein-bound drugs (>90% bound, such as warfarin at 99%) have a small free fraction, making them exquisitely sensitive to displacement interactions and changes in protein levels. Hypoalbuminemia (cirrhosis, nephrotic syndrome, malnutrition, critical illness, burns) increases the free fraction, potentially causing toxicity at 'therapeutic' total drug levels. Displacement interactions occur when two highly protein-bound drugs compete for binding sites (e.g., sulfonamides displacing bilirubin in neonates causing kernicterus). The clinical significance depends on the drug's volume of distribution and extraction ratio — displacement of drugs with low Vd and low hepatic extraction (like warfarin and phenytoin) produces clinically significant increases in free drug, while displacement of drugs with high Vd has minimal clinical effect because the released drug distributes into a large volume.